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Abstract
Background: The purpose of this article is to review and update the current developments of biologically active
dental implant surfaces and their effect on osseointegration.
Methods: PubMed was searched for entries from January 2006 to January 2016. Only in-vivo studies that
evaluated the effects of biomolecular coatings on titanium dental implants inserted into the bone of animals
or humans were included.
Results: Thirty four non-review studies provided data and observations were included in this review. Within
the criteria, four categories of biomolecular coatings were evaluated. The potential biomolecules include bone
morphogenetic proteins in 8 articles, other growth factors in 8 articles, peptides in 5 articles, and extracellular
matrix in 13 articles. Most articles had a healing period of 1 to 3 months and the longest time of study was
6 months. In addition, all studies comprised of implants inserted in animals except for one, which evaluated
implants placed in both animals and humans. The results indicate that dental implant surface modification with
biological molecules seem to improve performance as demonstrated by histomorphometric analysis (such as
percentage of bone-to-implant contact and peri-implant bone density) and biomechanical testing (such as
removal torque, push-out/pull-out tests, and resonance frequency analysis).
Conclusions: Bioactive surface modifications on implant surfaces do not always offer a beneficial effect on
osseointegration. Nevertheless, surface modifications of titanium dental implants with biomolecular coatings
seem to promote peri-implant bone formation, resulting in enhanced osseointegration during the early stages
of healing. However, long-term clinical studies are needed to validate this result. In addition, clinicians must
keep in mind that results from animal experiments need not necessarily reflect the human clinical reality.
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Background
Osseointegrated implants have been used to replace
missing teeth and as an anchorage for orthodontic tooth
movement with direct bone contact [1]. The concept of
osseointegration was originally introduced by Brånemark
et al. [2] in 1969. Albrektsson et al. [3] suggested that
this was “a direct functional and structural connection
between living bone and the surface of a load carrying
implant.” Another clinical definition provided by Zarb
and Albrektsson [4] proposed that osseointegration was
“a process whereby clinically asymptomatic rigid fixation
of alloplastic materials is achieved and maintained in
bone during functional loading.”
Surface modifications of titanium dental implants
have been studied and applied to improve biological
surface properties, which favors the mechanism of
osseointegration. Machined implant surfaces, represent-
ing the starting point of implant surface design, were
used for decades according to the classic protocols in
which several months were essential to achieve osseoin-
tegration [5]. Consequently, topographic and chemical
surface modifications replaced machined surfaces to a
* Correspondence: chien.60@osu.edu
3Division of Periodontology, College of Dentistry, The Ohio State University,
305 West 12th Avenue, Columbus, OH 43210, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Meng et al. Biomarker Research  (2016) 4:24 
DOI 10.1186/s40364-016-0078-z
great extent in clinical application [6]. Various methods
have been developed to increase the surface roughness
of dental implants, including blasting with ceramic
particles/acid etching [7, 8], titanium plasma spraying
[9, 10], electrochemical anodization [11, 12], and calcium
phosphate coatings [13, 14].
Furthermore, a novel research field investigating
the addition of bioactive molecules to titanium im-
plant surfaces has emerged in implant dentistry. A
bioactive molecule is a material having an effect on
or eliciting a response from living tissue [15]. Mole-
cules with potential to be applied for bioactive
purposes include bioceramics, ions, and biomolecules
[16–19]. In this review article, the research interest
was limited to titanium dental implants coated with
a biomolecule, an organic molecule that is produced
by a living organism.
Several reviews have been conducted to assess the ef-
fects of different implant surface modifications on peri-
implant bone formation and osseointegration [20, 21].
Although it has been reported that the use of bioactive
molecules represents a growing area of research in im-
plant dentistry with an aim of achieving quicker osseoin-
tegration [22, 23], there are questions that have not
previously been answered: (1) which type of biomolecu-
lar coatings are presently studied? and (2) what can we
expect as the possible effects of biomolecular coatings?
Consequently, these display the need for a broad review
focused on current developments of biologically active
dental implant surfaces. Therefore, the aim of this article
is to review and update the current developments of bio-
logically active dental implant surfaces and their impact
on osseointegration.
Materials and methods
Criteria for Considering Studies for This Review
Inclusion criteria
– Current developments published during January
2006 to January 2016
– In vivo study
– Titanium implant surfaces coated with biomolecules
– Threaded screw-type implants or implants with
recessions or indentations
– Evaluation of the effect of biomolecular coatings on
bone formation or osseointegration
Exclusion criteria
– In vitro study
– Use of biomolecules to fill the defect before or after
implant placement
– Cylindrical, non-threaded implants
– Intentional creation of peri-implant defects
– Evaluation of the effect of biomolecular coatings on
soft tissue, regeneration, ridge augmentation or sinus
floor elevation
– Implants that were loaded
Search Methods for Identification of Studies
Electronic searching
PubMed (January 2006 to January 2016) was searched
using the keywords “biologically active dental implant
surface,” “bioactive dental implant surface,” “dental im-
plant surface modification,” “bone morphogenetic pro-
teins (BMPs),” “growth factor,” “peptide,” “Arg-Gly-Asp
(RGD),” or “collagen.” Papers were limited to those arti-
cles published in English.
Hand searching
Reference lists of any potential studies were examined in
an attempt to identify any other studies.
Results
Among the available literature, 4 categories of biomolec-
ular coatings were outlined and assessed in this review:
(1) BMPs, (2) non-BMP growth factors, (3) peptides, and
(4) extracellular matrix (ECM).
Modification of dental implant surfaces with BMPs (Table 1)
Becker et al. [24] investigated bone formation onto
sand-blasted and acid-etched (control group), chromo-
sulfuric acid surface-enhanced (CSA group), and re-
combinant human BMP-2 (rhBMP-2) biocoated CSA
[BMP-A group: non-covalently immobilized rhBMP-2
(596 ng/cm2); BMP-B group: covalently immobilized
rhBMP-2 (819 ng/cm2)] implants after placement in the
mandibles and tibiae of dogs. After 4 weeks of healing,
bone to implant contact (BIC) values appeared to be
highest for the BMP-B group, followed by BMP-A, CSA
and the control in both the mandible and the tibia.
Bone density measured at a distance of less than 1 mm
adjacent to each implant revealed a similar pattern of
difference between groups as to that of BIC; however,
no differences between groups were observed at a
distance greater than 1 mm. It was concluded that
rhBMP-2 immobilized by covalent and noncovalent
methods on CSA-treated implant surfaces appeared to
be stable and stimulated direct bone apposition in a
concentration-dependent manner.
Lan et al. [25] investigated the influence of rhBMP-2
on bone-implant osseointegration in the femurs of rab-
bits. Thirty-two implants were evenly divided into 2
groups. Implants in group A were coated with 1.0 mg
rhBMP-2 and implants in group B were not coated with
rhBMP-2. Twelve weeks after implantation, the pull-out
binding strengths of group A were significantly greater
than that of group B. Scanning electronic microscopy
Meng et al. Biomarker Research  (2016) 4:24 Page 2 of 14
showed extensive mineralized matrixes on the surface of
the implants in group A but not B. Under confocal laser
scanning microscopy, there was significantly more per-
centage of marked bone adjacent to the implant surface
in group A compared to group B at both 4 and 8 weeks.
The authors concluded that rhBMP-2 improves the
quantity and quality of implant-bone osseointegration.
In the maxillae of adult miniature pigs, Liu et al. [26]
assessed the influence of BMP-2 and its mode of delivery
on the osteoconductivity of dental implants with 6 dif-
ferent types of surfaces, including uncoated titanium
(Ti) surfaces, BMP-2 adsorbed to uncoated Ti (Ti/BMP-
2 ads), calcium phosphate (CaP)-coated Ti surfaces
(CaPTi), BMP-2 adsorbed to CaPTi (CaPTi/BMP-2 ads),
Table 1 Surface modification of dental implants with BMPs
Author Animal – bone
site







1. C: sand-blasted and acid-etched
2. CSA
3. BMP-A: non-covalently immobilized
rhBMP-2 (596 ng/cm2)
4. BMP-B: covalently immobilized
rhBMP-2 (819 ng/cm2)
4 weeks BIC and BD: BMP-B > BMP-A > CSA > C
Lan et al.
[25]
Rabbit - femur 1. A: with rhBMP-2
2. B: without rhBMP-2
12 weeks - Pull-out strength: A (36.5 N) > B (27.6 N)
- Bone formation: A > B
Liu et al.
[26]
Pig – maxilla 1. Ti + CaP + BMP-2 inc
2. Ti + CaP + BMP-2 ads
3. Ti + CaP + BMP-2 ads + inc
4. Ti + CaP
5. Ti + BMP-2 ads
6. Ti
3 weeks - Bone volume was highest for Ti & CaP and lowest
for CaP/BMP-2 ads
- Bone-interface coverage of the implant surface
was highest for CaP and lowest for Ti/BMP-2 ads
Wikesjo
et al. [27]
Dog - mandible 1. TPO + rhBMP-2 (0.2 mg/ml) ads
2. TPO + rhBMP-2 (4.0 mg/ml) ads
3. TPO (control)
8 weeks % of BIC:
- TPO surfaces coated with 0.2 mg/ml
rhBMP-2: 43.3% vs. TPO control: 71.7%
- TPO surfaces coated with 4 mg/ml
rhBMP-2: 35.4% vs. TPO control: 68.2%
Wikesjo
et al. [28]
Monkey - maxilla 1. TPO + rhBMP-2 (2.0 mg/ml) ads
2. TPO + rhBMP-2 (0.2 mg/ml) ads
3. TPO (control)
16 weeks % of BIC
- Uncoated TPO surfaces: 74 - 75%
- TPO surfaces coated with 2.0 mg/ml rhBMP-2: 43%
- TPO surfaces coated with 0.2 mg/ml rhBMP-2: 37%
Huh et al.
[29]
Dog - mandible 1. rhBMP-2 coated implants
2. uncoated anodized implants
(control)
8 weeks % of BIC
- Uncoated control: 40.16%
- rhBMP-2 coated: 41.88%
Implant stability test
- Uncoated control: ISQ = 74.27
- rhBMP-2 coated: ISQ = 79.21
Hunziker
et al. [30]
Pig - maxilla 1. Ti
2. Ti + CaP
3. Ti + rhBMP-2 (10 μg) ads
4. Ti + CaP + rh BMP-2 (10 μg) ads
5. Ti + CaP + rh BMP-2 (12.95 μg) inc
6. Ti + CaP + rhBMP-2 ads + inc
1, 2, and 3 weeks Volume fraction of total bone
- Ti + CaP + BMP-2, with either ads or inc or both,
have the highest values at 1 week
- Ti + CaP + BMP-2 inc and Cap groups have
the highest values at 2 weeks
- Ti + CaP + BMP-2 inc and Cap groups have
the highest values at 3 weeks
Kim et al.
[31]
Dog - mandible 1. SLA (control)
2. SLA + rhBMP-2 (0.1 mg/mL)
3. SLA + rhBMP-2 (0.5 mg/mL)
4. SLA + rhBMP-2 (1 mg/mL)
8 weeks % of BIC
- Control: Buccal: 0.67%; Lingual: 23.37%
- rhBMP-2 (0.1 mg/mL): Buccal: 10.24%; Lingual: 26.50%
- rhBMP-2 (0.5 mg/mL): Buccal: 24.47%; Lingual: 35.45%
- rhBMP-2 (1 mg/mL): Buccal: 18.42%; Lingual: 33.43%
BV
- Control: Buccal: 2.77%; Lingual: 46.50%
- rhBMP-2 (0.1 mg/mL): Buccal: 13.30%; Lingual: 60.50%
- rhBMP-2 (0.5 mg/mL): Buccal: 33.67%; Lingual: 66.17%
- rhBMP-2 (1 mg/mL): Buccal: 35.67%; Lingual: 65.00%
Implant stability test
- Control: ISQ = 60.17
- rhBMP-2 (0.1 mg/mL): ISQ = 64.83
- rhBMP-2 (0.5 mg/mL): ISQ = 71.67
- rhBMP-2 (1 mg/mL): ISQ = 72.00
CSA chromosulfuric acid surface-enhanced; BIC bone to implant contact; BD bone density; Ti titanium; CaP calcium phosphate; BMP bone morphogenetic protein;
inc incorporated; ads adsorbed; TPO titanium porous oxide; SLA sandblasted and acid-etched surface
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BMP-2 incorporated into CaPTi (CaPTi/BMP-2 inc),
and BMP-2 adsorbed to and incorporated into CaPTi
(CaP/BMP-2 ads + inc). After 3 weeks, the volume of
bone deposited within the osteoconductive space was
highest for coated and uncoated implants with no BMP-
2, while the lowest value was achieved with coated im-
plants bearing only adsorbed BMP-2. Bone coverage of
the implant surface was highest for CaPTi, while the
lowest amount of bone coverage was observed for Ti/
BMP-2 ads. It was concluded that the osteoconductivity
of implant surfaces can be negatively modulated by
BMP-2 and its method of delivery.
Wikesjo et al. [27] studied whether adsorbing rhBMP-
2 onto a titanium porous oxide (TPO) implant surface
might increase or accelerate local bone formation and
support osseointegration in the posterior mandible
(type II bone) in dogs. Implants with a TPO surface
were adsorbed with rhBMP-2 at 0.2 mg/ml or 4.0 mg/
ml, whereas TPO implants without rhBMP-2 served as
controls. After 8 weeks of healing, implants coated with
rhBMP-2 (4.0 mg/ml) exhibited markedly increased
bone formation and bone metabolic activity compared
with that observed for implants coated with rhBMP-2
(0.2 mg/ml) and controls. BIC appeared significantly
lower for rhBMP-2-coated implants when compared to
the control, however, the BIC in BMP-2 coated im-
plants is clinically respectable. Finally, it was concluded
that rhBMP-2 adsorbed onto TPO implant surfaces is
able to induce dose-dependent peri-implant bone re-
modeling, resulting in the formation of normal, physio-
logic bone and clinically applicable osseointegration
within 8 weeks.
A similar study conducted by Wikesjo et al. [28] to
evaluate local bone formation and osseointegration in
the posterior maxillae (type IV bone) was analyzed in
8 adult monkeys. Each animal received three TPO im-
plants adsorbed with either rhBMP-2 at 2.0 mg/ml or
0.2 mg/ml in one quadrant and three TPO implants
without rhBMP-2 in the contra-lateral quadrant as
control. After 16 weeks, BIC was significantly higher
for uncoated TPO surfaces versus TPO surfaces
coated with either 2 mg/ml or 0.2 mg/ml rhBMP-2.
Additionally, rhBMP-2 coated TPO implants exhibited
a pinpoint BIC pattern regardless of rhBMP-2 concen-
trations; on the other hand, the controls exhibited a
thin layer of bone covering most of the implant
threads, resulting in higher BIC. Sites receiving
2.0 mg/ml of rhBMP-2 implants exhibited new peri-
implant bone formation, while contralateral controls
exhibited residual native bone close to the implant
surface. The authors concluded that rhBMP-2-coated
TPO surfaces enhanced local bone formation in type
IV bone in a dose-dependent fashion in non-human
primates, resulting in significant osseointegration.
Huh et al. [29] investigated anodized implants coated
with rhBMP-2 on the effect of bone formation in dogs.
Eighteen uncoated and 18 rhBMP-2 coated implants
were randomly installed into the mandibular alveolar
ridge of 6 young adult dogs for 8 weeks. The implant
stability quotient (ISQ) and histometric analysis were ex-
amined to evaluate the effect of rhBMP-2 on the stimu-
lation of bone formation. The BMP group showed
significantly higher ISQ values than the control group at
8 weeks after implant placement. Similarly, histometric
analysis indicated that the changes of bucco-lingual al-
veolar bone level were significantly higher in the BMP
group than in the control group. However, the differ-
ences in mean percentage of BIC and bone density were
not statistically significant. It was concluded that the
rhBMP-2 coated implants can enhance bone formation
and increase implant stability in dogs.
In the maxillae of adult miniature pigs, Hunziker et
al. [30] studied whether the capacity of BMP-2 to in-
duce peri-implant bone formation can be influenced
by its mode of delivery. Six different implant surfaces:
(1) Ti implant surface as control; (2) CaP coated Ti
implant; (3) BMP-2 (10 μg) adsorbed onto Ti implant;
(4) BMP-2 (10 μg) adsorbed onto CaP coated Ti im-
plant; (5) BMP-2 (12.95 μg) incorporated into CaP
coated Ti implant; and (6) BMP-2 (10 μg + 12.95 μg)
adsorbed onto and incorporated into CaP coated Ti
implant were established and tested in the maxillae of
18 adult miniature pigs. The histomorphometric ana-
lysis of bone formation was at 1, 2, and 3 weeks after
implant placement. The incorporated or adsorbed
BMP-2 on CaP coated Ti implant surface did not
benefit peri-implant bone formation compared to the
CaP coated Ti implant surface. However, the osteoin-
ductive efficacy of BMP-2 can be influenced by its
mode of delivery.
A study was conducted to investigate the effects of
rhBMP-2 on osseointegration in dogs [31]. Three differ-
ent concentrations of rhBMP-2 (0.1, 0.5, and 1 mg/mL)
were applied to sandblasted and acid etched (SLA) im-
plants and served as an experimental group, while SLA
implants were used as a control group. Two months
after tooth extraction, four animals received implants
coated with 3 different concentrations of rhBMP-2 in
one side of the mandible while the contralateral site
received SLA implants. BIC, bone volume (BV) and
implant stability were analyzed at 8 weeks after im-
plant placement. The mean BIC and BV were greater
in the 0.5 and 1.0 mg/mL rhBMP-2 groups than in the
0.1 mg/mL and control groups. Furthermore, the ISQ
values were highest in the 1.0 mg/mL group. It was
concluded that the SLA implants coating with 0.5 and
1.0 mg/mL of rhBMP-2 was more effective in enhan-
cing osseointegration.
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Modification of dental implant surfaces with non-BMP
growth factors (Table 2)
Anitua [32] compared BIC of titanium implant surface
(Ti) to human autologous plasma-rich growth factor-
coated titanium implants (PRGF) in the tibiae and radii of
goats. Histomorphometry analysis performed after 8 weeks
showed that titanium implant surfaces with PRGF demon-
strated significantly higher percentage of BIC. Every bi-
opsy of the implants made with PRGF revealed bone
surrounding the entire implant; whereas non-PRGF-
coated implants were surrounded by cortical bone only in
the middle third. Furthermore, 1391 implants were bioac-
tivated with PRGF and installed in 295 patients. The au-
thor reported that 99.6% of the implants treated with
PRGF were well osseointegrated. It was concluded that
osseointegration was enhanced by covering the implant
surface with PRGF before insertion into the alveolar bone.
Lan et al. [33] studied the effect of combining rhBMP-
2 and recombinant human basic fibroblast growth factor
(rhbFGF) or recombinant human insulin-like growth
factor-1 (rhIGF-1) on bone-implant osseointegration in
rabbits. Sixty-four implants were coated with polylactic
acid and equally divided into 4 groups. Implants in
group 1 were applied with 1.0 mg rhBMP-2 and 200 μg
rhbFGF, group 2 with 1.0 mg rhBMP-2 and 250 μg
rhIGF-1, group 3 with only 1.0 mg rhBMP-2, and group
4 were used as controls and had no growth factors
applied. During the healing period, fluorescent bone
markers were administered at 4 and 8 weeks. Twelve
weeks after the implantation in the femurs of rabbits,
implants and surrounding bone were collected and pre-
pared for confocal laser scanning microscopy analysis.
There was a statistical difference in bone formation
between rhBMP-2 and non-rhBMP-2 groups at 4 or
8 weeks. The new bone formation in groups 1 and 2 was
greater than that of group 3 at 8 weeks. It was concluded
that rhBMP-2 could increase new bone formation and
was able to act synergistically with rhbFGF and rhIGF-1
to improve osseointegration.
In a rabbit tibia model, Park et al. [34] evaluated the
bone response around anodized titanium implants
coated with fibroblast growth factor-fibronectin (FGF-
FN) fusion protein. Twenty implants were evenly divided
into 2 groups. Implants in group 1 were anodized under
a constant voltage of 300 V, whereas implants in group 2
were anodized under a constant voltage of 300 V and
then soaked in a solution containing FGF-FN (65 μg/
mL) for 24 h. After 12 weeks of healing, the mean re-
moval torque value for group 2 was significantly greater
than that of group 1. Under histomorphometric analysis,
the percentage of BIC was significantly higher in group
2 than in group 1. The authors concluded that the
FGF-FN fusion protein coating on anodized implants
may enhance osseointegration.
Nikolidakis et al. [35] examined the effect of trans-
forming growth factor β1 (TGF-β1) on the early bone
healing around dental implants installed into the femoral
condyle of goats. Eight healthy female goats were used
in this study, and each animal received 3 implants: one
Ti (control), one Ti loaded with 0.5 μg TGF-β1 (Ti-
TGF0.5), and one Ti loaded with 1.0 μg TGF-β1 (Ti-
TGF1.0). Six weeks after implantation, an intervening
fibrous tissue layer occurred around approximately half of
the TGF-β1 loaded implants. Ti implants without TGF-β1
treatment demonstrated the highest percentage of BIC,
while implants with 1.0 μg TGF-β1 showed the lowest
amount. The difference between the two aforementioned
groups was statistically significant. The authors concluded
that a low dose of TGF-β1 has a negative influence on the
integration of oral implants in trabecular bone during the
early post-implantation healing phase.
Schouten et al. [36] investigated the effect of implant
design, surface properties, and TGF-β1 on peri-implant
bone response. Two geometrically different implant
types, screw type (St) and push-in type (Pi), were used.
Additionally, the implant surfaces were modified with an
electrosprayed CaP coating, either enriched or not
enriched with TGF-β1. A total of 54 implants, equally
divided into six groups, were installed into the femoral
condyles of nine goats for 12 weeks. With respect to im-
plant geometry, St implants showed an overall better
biological healing process than Pi implants. In term of
surface properties, the deposition of CaP coating signifi-
cantly increased percentage of BIC for both implant
types. The enrichment of CaP-coated implants with
TGF-β1, however, did not significantly improve peri-
implant bone response. The authors concluded that an
extensive improvement of the bone response to titanium
implants can be obtained by adding an electrosprayed
CaP coating. The supplementation of a 1 μg TGF-β1
coating has only a marginal effect.
Lee et al. [37] analyzed the effect of poly(lactide-co-
glycolide) (PLGA) in combination with bFGF coating on
an anodized titanium implant surface by electrospray.
Forty-eight implants were equally divided into 4 groups
and inserted into rabbit tibiae. Group 1 implants were
anodized under 300 V; group 2 implants were anodized
and then coated with 0.02 ml PLGA; group 3 implants
were anodized and then coated with 0.02 ml PLGA/
bFGF (10 ng bFGF); and group 4 implants were anod-
ized and then coated with 0.2 ml PLGA/bFGF (100 ng
bFGF). Histomorphometric analysis was performed via
light microscopy and computerized image analysis of the
implants that had been in situ for 12 weeks. Implants
in group 4 (44.7%) had significant higher mean BIC
percentage than that seen in groups 1 (31.4%) and 2
(33.6%). It was suggested that coating a titanium implant
with PLGA incorporated with bFGF by electrospray
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Table 2 Surface modification of dental implants with other growth factors
Author Animal – bone
site
Mode of surface modification Length
of study
Findings
Anitua [32] Goat – tibia
and radius
1. Ti (control)
2. Ti + PRGF
8 weeks % of BIC




Rabbit - femur 1. Group 1: rhBMP-2 (1.0 mg) + rhbFGF (200 μg)
2. Group 2: rhBMP-2 (1.0 mg) + rhIGF-1 (250 μg)
3. Group 3: rhBMP-2 (1.0 mg)
4. Group 4: no growth factor (control)
4 and
8 weeks
% of new bone formation
- Group 1: 7.0% at 4 weeks, 10.0% at 8 weeks
- Group 2: 7.6% at 4 weeks, 9.9% at 8 weeks
- Group 3: 6.2% at 4 weeks, 8.0% at 8 weeks
- Group 4: 5.0% at 4 weeks, 6.0% at 8 weeks
Park et al.
[34]
Rabbit - tibia 1. Group 1: anodized under constant
300 voltage
2. Group 2: anodized under constant 300
voltage + FGF-FN fusion protein (65 μg/mL)
12 weeks Mean removal torque value
- Group 1: 37.6 Ncm
- Group 2: 44.8 Ncm
% of BIC
- Group 1: 76.4%






2. Ti-TGF(0.5): Ti + 0.5 μg TGF-β1
3. Ti-TGF(1.0): Ti + 1.0 μg TGF-β1








1. Screw type implant: St
2. St + CaP
3. St + CaP + TGF-β1 (1.0 μg)
4. Push-in type implant: Pi
5. Pi + CaP
6. Pi + CaP + TGF-β1 (1.0 μg)
12 weeks % of BIC
- St: 44%
- St + CaP: 58%
- St + CaP + TGF-β1: 64%
- Pi : 23%
- Pi + CaP: 46%
- Pi + CaP + TGF-β1: 52%
Lee et al.
[37]
Rabbit – tibia 1. Group 1: anodized (under 300 voltage)
2. Group 2: anodized + 0.02 ml PLGA
3. Group 3: anodized + 0.02 ml PLGA/bFGF
(10 ng bFGF)
4. Group 4: anodized + 0.2 ml PLGA/bFGF
(100 ng bFGF)
12 weeks % of BIC
- Groups 1: 31.4%
- Group 2: 33.6%
- Group 3: around 37%







3. CaP + rhBMP-2 inc
4. CaP + rhVEGFI65 inc
5. CaP + rhBMP-2 inc + rhVEGFI65 inc
1, 2, and
4 weeks
% of BIC for ROI 1 + 4
- AE: 3.4% at 1 week; 11.5% at 2 weeks; 16.1% at 4 weeks
- CaP: 5.2% at 1 week; 19.2% at 2 weeks; 23.5% at 4 weeks
- CaP + BMP-2: 1.8% at 1 week; 15.5% at 2 weeks; 21.6%
at 4 weeks
- CaP + VEGF: 3.1% at 1 week; 15.2% at 2 weeks; 22.6% at
4 weeks
- CaP + BMP-2 + VEGF: 3.3% at 1 week; 22.1% at 2 weeks;
23.2% at 4 weeks
% of BIC for ROI 2 + 3
- AE: 10.6% at 1 week; 14.6% at 2 weeks; 20.1% at
4 weeks
- CaP: 15.4% at 1 week; 22.6% at 2 weeks; 24.9% at
4 weeks
- CaP + BMP-2: 8.2% at 1 week; 27.3% at 2 weeks; 23.6%
at 4 weeks
- CaP + VEGF: 8.5% at 1 week; 23% at 2 weeks; 24.4% at
4 weeks
- CaP + BMP-2 + VEGF: 9.6% at 1 week; 31.7% at 2 weeks;
31.8% at 4 weeks
Schliephake
et al. [39]
Rat - tibia 1. SAE (control)
2. SAE + OAS




% of BIC for 1 and 4 weeks
- SAE: 14.5% at 1 week; 40.6% at 4 weeks
- SAE + OAS: 14.1% at 1 week; 40.2% at 4 weeks
- SAE + OAS + VEGF: 15.1% at 1 week; 60.1% at 4 weeks
% of BIC for 13 weeks
All groups were between 75% to 80% with no
significantly differences between groups
Ti titanium implant surface; BIC bone to implant contact; PRGF human plasma-rich growth factor; hrBMP-2 recombinant human bone morphogenetic protein-2;
rhbFGF recombinant human basic fibroblast growth factor; rhIGF-1 recombinant human insulin-like growth factor; FGF-FN fibroblast growth factor-fibronectin;
TGF-β1 transforming growth factor β1; St screw type implant; Pi push-in type implant; CaP calcium phosphate coating; PLGA poly(lactide-co-glycolide); bFGF
basic fibroblast growth factor; AE acid-etched; VEGF vascular endothelial growth factor; CaP calcium phosphate; SAE sandblasted and acid-etched; OAS DNA
oligonucleotide anchor strands
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may enhance bone formation near the surface of an im-
plant installed in bone.
Ramazanoglu et al. [38] studied whether coating implant
surfaces with rhBMP-2 and recombinant human vascular
endothelial growth factor I65 (rhVEGFI65) affects osseoin-
tegration in pigs. Five different groups of implants: (1)
acid-etched surface (AE; control group); (2) CaP coated
surface (CaP group); (3) CaP bearing incorporated
rhBMP-2 (BMP group); (4) CaP bearing incorporated
rhVEGFI65 (VEGF group); and (5) CaP bearing incorpo-
rated rhBMP-2 + rhVEGFI65 (BMP+VEGF group) were
established and tested in the frontal skulls of 9 pigs.
Osseointegration was assessed by histomorphometric ana-
lysis of bone formation at 1, 2, and 4 weeks. At 2 weeks,
the BMP and BMP +VEGF groups showed significant en-
hancement in BV density compared to the AE control
group. All implants with CaP coating demonstrated sig-
nificant enhanced BIC rates compared with the AE con-
trols at 2 weeks. However, the BMP +VEGF group did not
significantly enhance BIC at 4 weeks. It was concluded
that the biomimetic CaP coated implant surfaces with
both BMP and VEGF enhances BV density, but not BIC.
Schliephake et al. [39] tested whether rhVEGF stimu-
lates peri-implant bone formation in rats. Three different
implant surfaces: (1) sandblasted acid-etch (SAE) im-
plants; (2) SAE implants coated with DNA oligonucleo-
tide anchor strands (SAE +OAS); and (3) SAE + OAS
hybridized with rhVEGF-conjugated to complementary
oligonucleotide strands, were studied in the tibiae of 36
rats. The BIC and BD were assessed 1, 4, and 13 weeks
after implant placement. Implant surfaces with rhVEGF
hybridization showed the highest BIC 1 month after
implant placement. It was concluded that rhVEGF can
accelerate BIC to a certain extent.
Modification of dental implant surfaces with peptides
(Table 3)
Germanier et al. [40] investigated whether implant sur-
faces with Arg-Gly-Asp (RGD)-peptide-modified poly-
mer could enhance early bone apposition in the
maxillae of miniature pigs. Test and control implants
had the same microrough structure identical to SLA
surfaces, but differed in their surface chemistry coating.
Four different implant surfaces: (1) SLA without
Table 3 Surface modification of dental implants with peptides
Author Animal – bone
site
Surface modification Length of study Findings
Germanier
et al. [40]
Pig – maxilla 1. SLA (control)
2. SLA + PLL-g-PEG
3. SLA + PLL-g-PEG/PEG-RDG
4. SLA + PLL-g-PEG/PEG-RGD
2 and 4 weeks % of BIC
- SLA: 43.6% at 2 weeks, 62.5% at 4 weeks
- SLA + PLL-g-PEG: 55.9% at 2 weeks, 67.4% at 4 weeks
- SLA + PLL-g-PEG/PEG-RDG: 48.5% at 2 weeks, 75.5% at
4 weeks




Dog – mandible 1. A: microstructured + HA + low
concentrated (20 μg/ml) peptide
2. B: microstructured + HA
3. C: microstructured
4. D: microstructured + HA + high
concentrated (200 μg/ml) peptide



















- Control: 50.2%, 58.5%, and 60.9% at 4, 8, and 12 weeks,
respectively




Pig – forehead 1. Group A: HA
2. Group B: HA + P-15 (20 μg/ml)
3. Group C: HA + P-15 (200 μg/ml)
14 and 30 days % of BIC for ROI A and ROI B, respectively
- A: 63.8 & 76.7% at 14 days, 70.9 & 75.8% at 30 days
- B: 72.1 & 72.5% at 14 days, 69.9 & 74.6% at 30 days
- C: 88.2 & 88.7% at 14 days, 80.5 & 88.5% at 30 days
BD for ROI A and ROI B, respectively
- A: 49.5 & 36.2% at 14 days, 38.4 & 28.7% at 30 days
- B: 44.0 & 31.6% at 14 days, 45.7 & 42.9% at 30 days
- C: 44.9 & 36.1% at 14 days, 47.2 & 44.5% at 30 days
Yoo
et al. [44]
Rabbit - tibia 1. Anodized Ti implant (control)
2. PLGA/rhBMP-2 coated
3 and 7 weeks % of BIC (total)
- Control: 27.26% at 3 weeks; 31.47% at 7 weeks
- PLGA/rhBMP-2: 34.69% at 3 weeks; 35.32% at 7 weeks
SLA sandblasted and acid-etched surface; PLL-g-PEG poly(L-lysine)-graft-poly(ethylene glycol); RDG Arg-Asp-Gly; RGD Arg-Gly-Asp; BIC bone to implant contact;
BD bone density; HA hydroxyapatite; P-15 P-15 peptide; ROI region of interest
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coating as control; and coating with (2) poly(L-lysine)-
graft-poly(ethylene glycol) (PLL-g-PEG); (3) PLL-g-PEG/
PEG-RGD; or (4) PLL-g-PEG/PEG-Arg-Asp-Gly(RDG)
were examined histomorphometrically for osteoblastic
activity and bone apposition. The RGD-modified
implants demonstrated significant increase in BIC ap-
position at 2 weeks as compared with the controls.
However, no further significant increase in percentage
of BIC was observed in RGD-coated implants at 4 weeks
as compared to the controls. On the contrary, the PEG
and PEG/RDG groups did show significantly higher
BIC than the control group at 4 weeks. It was con-
cluded that the PLL-g-PEG/PEG-RGD coatings may
stimulate greater bone apposition in the very early
stages of bone healing following implant placement.
Barros et al. [41] analyzed the effect of a biofunctio-
nalized implant surface on osseointegration in the man-
dibles of dogs for 12 weeks. All implants were lined by
the same microrough surface topography provided by
the grit-blasting/acid-etching process to create a micro-
structured surface. For biofunctionalization of the im-
plant surface, a low or high concentration of bioactive
peptide was absorbed to hydroxyapatite (HA) coatings.
Thus, 4 different types of implant surfaces were tested:
(1) micro-structured + HA + a low concentration of bio-
active peptide (20 μg/mL); (2) micro-structured + HA;
(3) micro-structured; and (4) micro-structured + HA + a
high concentration of bioactive peptide (200 μg/mL).
Implants with 200 μg/mL peptide had the highest mean
value of direct BIC, but no statistically significant dif-
ferences were detected between the groups. In addition,
bone density analysis revealed that implant surfaces
with 20 μg/mL peptide provided a higher adjacent bone
density when compared to the other groups. Neverthe-
less, the differences between the groups were also not
statistically significant. The authors concluded that bio-
functionalization of the implant surface might interfere
in the bone apposition around implants, especially re-
garding the aspect of bone density.
Yang et al. [42] compared the ability of uncoated ti-
tanium implant surfaces with RGD-coated surfaces to
bond to bone in the femurs and tibiae of rabbits. Sixty
implants (30 uncoated control and 30 RGD-coated)
were inserted into the femurs of 30 rabbits, and 30 im-
plants (15 control and 15 RGD-coated) were installed
into the tibias of 15 rabbits. The RGD-coated implants
exhibited significantly greater percentages of BIC than
those of the control implants at 4, 8, and 12 weeks
after implantation. In addition, the RGD-coated im-
plants revealed statistically significant higher removal
torque values at 8 and 12 weeks. It was concluded that
RGD-coated implants have a positive effect on bone-
bonding ability by producing higher BIC and removal
torque values.
Lutz et al. [43] studied the influence of a P-15 peptide
coated implant on early implant osseointegration in
adult pigs for a period of 14 and 30 days. All surfaces of
dental implants were grit-blasted and acid-etched
followed by HA coating. For the implants in the test
group, two concentrations of P-15 (20 μg/ml and
200 μg/ml) were bound to the HA surface. Implants
without P-15 coating served as the control group. Im-
plants with the 200 μg/ml P-15 had significantly higher
value of BIC at 14 and 30 days compared with the other
groups. Both concentrations of P-15 revealed better
peri-implant bone density compared to the control
group at 30 days. It was concluded that biofunctionaliza-
tion of the implant surface with a biomimetic active pep-
tide has a positive effect on osseointegration by creating
higher percentages of BIC at 14 and 30 days and greater
peri-implant bone density at 30 days.
Yoo et al. [44] examined whether biochemical coating
of anodized Ti implant surface with poly(lactide-co-gly-
colide) (PLGA) and BMP-2 stimulates bone growth in
rabbits. Eighteen of each group – anodized Ti implants
(control group) and implants coated with 80 μL of PLGA
and 50 μg/mL of rhBMP-2 (experimental group) – were
placed in the tibiae of 8 rabbits for 3 and 7 weeks. Under
histomorphometric analysis, the BIC was significantly
higher in the PLGA/BMP-2 group than those of the con-
trol group at 3 weeks. However, the significant difference
disappeared at 7 weeks. The authors concluded that
PLGA/BMP-2 coated implants facilitated osseointegra-
tion during early healing.
Modification of dental implant surfaces with ECM (Table 4)
Morra et al. [45] investigated whether biochemical modi-
fication of the anodized titanium surfaces with collagen
(ColpTi) has a positive effect on osseointegration in
rabbit femur trabecular bone. Histomorphometric ana-
lysis revealed that a higher amount of bone inside the
screw threads and in contact with the surface was
observed on ColpTi implants at 4 weeks. ColpTi had a
significantly higher percentage of BIC compared to the
control anodized titanium surface. They concluded that
osseointegration in trabecular bone can be enhanced by
biochemical surface modification with collagen.
Schliephake et al. [46] examined whether a composite
coating of calcium phosphate and mineralized collagen I
could enhance peri-implant bone formation. Four types
of implants were evaluated in the mandibles of dogs for
3 months by measuring BIC and BV density (BVD). The
control group comprised of implants with an uncoated
machined titanium surface. The modified groups in-
cluded implants coated with HA, collagen I, or a com-
posite coating of HA and mineralized collagen I. After
1 month, the percentage of BIC was significantly higher
only in the group of implants with the composite
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Table 4 Modification of dental implant surfaces with ECM
Author Animal – bone
site





Rabbit – femur 1. pTi: anodization of titanium implant
2. ColpTi: collagen coated titanium implant
4 weeks % of BIC
- pTi: 36.9%
- ColpTi: 63.7%





Dog - mandible 1. Machined titanium surface (control)
2. Machine + Collagen I (collagen only)
3. Machine + calcium phosphate (HA-only)





- Control: 31.5% at 1 month, 41.2% at 3 months
- Collagen-only: 41.9% at 1 month, 60.2% at 3 months
- HA-only: 45.2% at 1 month, 61.7% at 3 months
- Composite: 62.6% at 1 month, 59.0% at 3 months
BVD
- Control: 16.1% at 1 month, 40.6% at 3 months
- Collagen-only: 22.9% at 1 month, 62.6% at 3 months
- HA-only: 33.0% at 1 month, 58.5% at 3 months
- Composite: 40.9% at 1 month, 67.3% at 3 months
Stadlinger
et al. [47]
Pig – mandible 1. Coll: collagen type I
2. Coll/CS: collagen type I + chondroitin sulfate
3. Coll/CS/BMP: collagen type I + chondroitin
sulfate + BMP-4




Implant stability test at 22 weeks
- Coll: ISQ = 73
- Coll/CS: ISQ = 69
- Coll/CS/BMP: ISQ = 67
Ferguson
et al. [48]
Sheep – pelvis 1. Ti: sandblasted and acid-etched titanium
2. Zir: sandblasted and etched zirconia
3. CaP: Ti coated with calcium phosphate
4. APC: Ti modified via anodic plasma-chemical
treatment
5. Bisphos: bisphosphonate coated Ti
6. Coll/CS: Ti coated with collagen containing
chondroitin sulfate









Pig – mandible 1. Coll: collagen coated Ti
2. Coll/DC: collagen + DC
3. Coll/CS: collagen + CS
4. Coll/DC/TGF: collagen + DC + TGF- β1
5. Coll/CS/BMP: collagen + CS + BMP-4
6. Coll/DC/CS/BMP/TGF: collagen + DC + CS +
BMP-4 + TGF- β1
3, 4, 5 and
6 weeks









Pig – mandible 1. Coll: collagen
2. Coll/CS: collagen + CS
3. Coll/CS/BMP-4: collagen + CS + rhBMP-4






Sheep – pelvis 1. Control: sandblasted and acid-etched Ti
2. CaP: calcium phosphate coated
3. APC: plasma anodized
4. Coll/CS: collagen + CS coated
5. Bisphos: bisphosphonate coated
6. Zir: sandblasted and etched zirconia
8 weeks - All implants were well osseointegrated
- No significant differences in % of BIC
Schliephake
et al. [52]
Dog – mandible 1. MS: machined surface
2. DAE: dual acid-etched surface
3. RGD: RGD + DAE
4. Coll: collagen I + DAE
5. Coll/CS: collagen I + CS + DAE




- MS: 25.4% at 4 weeks, 37.7% at 12 weeks
- DAE: 40.9% at 4 weeks, 57.6% at 12 weeks
- RGD: 41.4% at 4 weeks, 59.4% at 12 weeks
- Coll: 40.4% at 4 weeks, 56.3% at 12 weeks
- Coll/CS: 31.1% at 4 weeks, 66.4% at 12 weeks
- Coll/CS/BMP-2: 43.7% at 4 weeks, 60.6% at 12 weeks
Stadlinger
et al. [53]
Pig – mandible 1. Control: sandblasted and acid-etched Ti
2. Coll/CS1: Ti + collagen + low dose CS
3. Coll/CS2: Ti + collagen + high dose CS
1 and
2 months
% of BIC for the entire implant at 1 and 2 months
- Control: 51.6% at 1 month, 62.7% at 2 months
- Coll/CS1: 68.4% at 1 month, 71% at 2 months
- Coll/CS2: 63.1% at 1 month, 67.9% at 2 months
Meng et al. Biomarker Research  (2016) 4:24 Page 9 of 14
coating of calcium phosphate and mineralized collagen
I. All coated implants showed significantly higher BVD
of newly formed peri-implant bone after 1 month. Both
BIC and BVD were significantly greater in all coated
implants compared to the controls after 3 months. The
authors concluded that coating an implant by biomime-
tically combining collagen I and HA can enhance BIC
and peri-implant bone formation.
Stadlinger et al. [47] studied whether the application
of chondroitin sulfate in combination with type I colla-
gen, with or without BMP-4, can augment ossification
and thus improve implant stability. One hundred and
twenty implants were placed in the mandibles of 20
miniature pigs for 6 months. Three different surface
coatings were produced: (1) collagen type I (coll); (2)
coll/chondroitin sulfate (coll/CS); and (3) coll/CS/BMP-
4 (coll/CS/BMP). Six implants (2 of each type of sur-
face) were randomly installed on either side of the
mandible in each minipig. The histomorphometry
results demonstrated that the percentage of BIC was
highest for coll/CS, followed by coll and coll/CS/BMP.
The implant stability, as measured by resonance fre-
quency analysis (RFA), was highest in the coll group.
Although statistically significant differences were not
observed in both BIC and RFA, coll and coll/CS
implant coatings had a positive trend in beneficial char-
acteristics for osseointegration, compared with the fur-
ther integration of BMP-4.
Using a sheep pelvis model, Ferguson et al. [48] tested
6 different implant surface modifications and their effect
on implant osseointegration at 2, 4, and 8 weeks after
implantation. Peri-implant bone density and removal
torque were analyzed on 6 different implant surfaces:
(1) sandblasted and acid-etched titanium (Ti), (2) sand-
blasted and acid-etched zirconia, (3) Ti coated with
calcium phosphate (CaP), (4) Ti modified via anodic
plasma-chemical treatment (APC), (5) bisphosphonate-
coated Ti (Bisphos), and (6) Ti coated with collagen
containing chondroitin sulfate (Coll/CS). No significant
differences in peri-implant bone density were identified
between groups. Removal torque values for Ti, CaP,
Bisphos and Coll/CS were significantly higher than
those for zirconia and APC at 8 weeks after implant
placement. The authors suggested that biofunctional
coating of the implant surface with calcium phosphate,
bisphosphonate or collagen containing chondroitin
sulfate seems to have the potential to enhance peri-
implant bone healing, but no additional benefit can be
shown when compared to the effectiveness of SLA sur-
face modification.





1. Ti: acid-etched titanium
2. CollTi: collagen type I + Ti
2 and
4 weeks
% of BIC was significantly higher around CollTi when
compared with Ti both in femur and tibia at 2 weeks.
No significant differences were observed at 4 weeks.
Alghamdi
et al. [55]
Dog - mandible 1. Ti (control)
2. Nano-CaP-coated




- Ti: 47.5% at 4 weeks; 65.1% at 12 weeks
- Nano-CaP: 49.5% at 4 weeks; 67.2% at 12 weeks
- Collagen: 61.4% at 4 weeks; 72.7 at 12 weeks
Inner zone BV
- Ti: 10.5% at 4 weeks; 37.5% at 12 weeks
- Nano-CaP: 23.1% at 4 weeks; 38.2% at 12 weeks
- Collagen: 28.4% at 4 weeks; 52.4 at 12 week
Stadlinger
et al. [56]
Pig - maxilla 1. SAE
2. Collagen type I coating (Coll)
3. Coll + CS (low amount)
4. Coll + CS (high amount)
5. Coll + high-SH




- SAE: 56% at 4 weeks; 66.4% at 8 weeks
- Coll: 36.8% at 4 weeks; 68.7% at 8 weeks
- Coll + CS (low): 70.4% at 4 weeks; 74.7% at 8 weeks
- Coll + CS (high): 51.2% at 4 weeks; 63.5% at 8 weeks
- Coll + high-SH: 50.3% at 4 weeks; 64.3% at 8 weeks
- Coll + low-SH: 53.9% at 4 weeks; 65.5% at 8 weeks
BVD
- SAE: 23.2% at 4 weeks; 45.2% at 8 weeks
- Coll: 26.2% at 4 weeks; 48.9% at 8 weeks
- Coll + CS (low): 28.1% at 4 weeks; 54.9% at 8 weeks
- Coll + CS (high): 27.4% at 4 weeks; 45.2% at 8 weeks
- Coll + high-SH: 23.6% at 4 weeks; 42.9% at 8 weeks
- Coll + low-SH: 21.8% at 4 weeks; 46.9% at 8 weeks
Lee
et al. [57]
Rabbit - tibia 1. AE (control)
2. HA coating
3. Coll + HA coating
4. Coll + HA + BMP-2 coating
6 weeks % of BIC
- AE: 21.38%
- HA coating: 24.18%
- Coll + HA coating: 41.45%
- Coll + HA + BMP-2 coating: 30.72%
ECM extracellular matrix; HA hydroxyapatite; BVD newly formed peri-implant bone; BMP-4 bone morphogenetic protein-4; Ti titanium implant; ISQ implant stability
quotient; CaP calcium phosphate; Bisphos bisphosphonate; CS chondroitin sulfate; DC decorin; TGF-β1 transforming growth factor β1; rhBMP-4 recombinant human
bone morphogenetic protein-4; RGD RGD peptide; SH sulfate hyaluronan; AE acid-etched
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Stadlinger et al. [49] examined whether implants
coated with extracellular matrix (ECM) components
could improve osseointegration in pigs. The 6 surface
coatings tested in this study were: (1) collagen (coll); (2)
collagen and decorin (coll/DC); (3) collagen and chon-
droitin sulfate (coll/CS); (4) coll/DC and TGF-β1 (coll/
DC/TGF); (5) coll/CS and BMP-4 (coll/CS/BMP); and
(6) coll/CS/DC, TGF-β1 and BMP-4 (coll/CS/DC/BMP/
TGF). Eight miniature pigs each received 6 implants in
the mandible. The highest BIC was observed in coll/CS
or coll/CS/BMP coated implants during the 6 weeks of
healing, and was statistically higher at weeks 5 and 6
compared to other coatings. The authors implied that
implant surfaces coated with coll/CS and coll/CS/BMP
could lead to a higher degree of bone formation com-
pared to other ECM components.
Stadlinger et al. [50] tested whether the addition of
chondroitin sulfate (CS) and rhBMP-4 on a collagen-
coated (coll) implant could further improve osseointe-
gration in pigs. One hundred and twenty implants with
3 distinct surface coatings (coll, coll/CS, and coll/CS/
rhBMP-4) were placed into the mandibles of 20 mini-
pigs. The percentage of BIC was measured 6 months
after implantation by histomorphometric analysis. The
highest percentage of BIC was observed in coll/CS
(40%), followed by coll (30%) and coll/CS/rhBMP-4
(27%). The authors suggested that the addition of CS to
a collagen coated implant could promote osseointegra-
tion. However, further inclusion of a fairly low amount
of rhBMP-4 had a negative effect on bone formation
compared to coll/CS.
Langhoff et al. [51] compared 6 modified implant sur-
faces for osseointegration in a sheep pelvis model for
8 weeks. The six types of dental implant surfaces tested
in this study were: (1) sandblasted and acid-etched (con-
trol), (2) calcium phosphate (CaP), (3) plasma anodized
(APC), (4) type I collagen + chondroitin sulfate (coll/CS),
(5) bisphosphonate (BisP), and (6) zirconia (Zr). All
tested implants revealed decent osseointegration with
only slight differences compared to the control implant
surfaces. New bone formation was observed around all
tested implants in the cancellous bone by 2 weeks and
built up steadily until 8 weeks. The authors concluded
that there were no significant differences in osseointe-
gration between the six different implant surfaces.
However, there was a clear tendency for col/CS, CaP
and BisP to show better BIC values at 8 weeks com-
pared to APC or Zr.
In the mandibles of foxhounds, Schliepake et al. [52]
evaluated whether organic coatings on an implant
surface could enhance peri-implant bone formation. Six
types of implants were examined histomorphometrically
in each foxhound: (1) machined surface (MS), (2) dual
acid-etched surface (DAE), (3) DAE coated with RGD
(RGD), (4) DAE coated with type I collagen (coll), (5)
DAE coated with coll and chondroitin sulfate (coll/CS),
and (6) coll/CS and rhBMP-2 (coll/CS/BMP-2). After
1 month, all coated implant groups exhibited signifi-
cantly higher BIC values than that of the MS group, but
not from that of the DAE group. After 3 months, with
the exception of the coll group, the same held true for
the mean BIC of all coated DAE groups. The mean BVD
of the newly formed peri-implant bone did not reach a
significant difference among any of the surfaces in 1 and
3 months. The authors concluded that organic coatings
with coll, RGD, or CS with or without rhBMP-2 on DAE
implant surface did not enhance peri-implant BV density
when compared with the DAE surfaces, but did improve
BIC when compared with the MS surfaces. It appears
that the organic coatings did not offer further benefits
than the benefits of DAE surfaces.
Stadlinger et al. [53] investigated whether coating an
implant surface with collagen and chondroitin sulfate
would enhance bone formation and implant stability,
compared with an uncoated control. Three different im-
plant surfaces, (1) sandblasted acid-etched implants
(control), (2) collagen with low dose chondroitin sulfate
(CS1), and (3) collagen with high dose chondroitin sul-
fate (CS2), were tested in the mandibles of 20 minipigs.
Bone formation was determined by the percentage of
BIC and relative peri-implant BV density (rBVD) after 1
and 2 months of healing, whereas implant stability was
measured by RFA. Coated implants had significantly
higher BIC compared with controls after 1 month of
healing, but no significant difference could be found
between CS1 and CS2. The percentage of BIC was in-
creased for all surfaces after 2 months of healing; how-
ever, no significant differences were identified among
the three groups. Similarly, no statistical differences in
rBVD and RFA were found. It was concluded that colla-
gen/CS has an encouraging effect on bone formation in
short-term healing.
Morra et al. [54] investigated the effect of collagen co-
valently linked to acid-etched implants on peri-implant
bone formation. Implants were installed in rabbit femurs
and tibiae for up to 4 weeks. Histomorphometric ana-
lysis at 2 weeks revealed that significantly higher BIC
was observed in collagen coated implants both in femurs
and tibiae. On the other hand, no significant differences
in BIC were detected at 4 weeks. The authors concluded
that type I collagen covalently linked to acid-etched
Ti implant surfaces could enhance peri-implant bone
formation during early healing.
In the mandibles of dogs, Alghamdi et al. [55] evalu-
ated whether type I collagen improves peri-implant bone
formation. Three types of implants: (1) non-coated Ti
implants; (2) nano-CaP-coated Ti implants; and (3) type
I collagen-coated implants were placed in the mandibles
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of 16 beagle dogs 3 months after tooth extraction. Both
histomorphometry and micro-CT were measured to
evaluate peri-implant bone formation at 4 and 12 weeks
after implant placement. Three different zones (inner: 0-
300 μm; middle: 300-600 μm; and outer: 600-1000 μm)
of bone around the implant surfaces were assessed.
Nano-CaP and collagen-coated implants demonstrated a
significantly higher BV in the inner zone compared to
non-coated implants at 4 weeks. However, no significant
difference was identified in the BV between all groups
at 12 weeks as indicated by both histomorphometric
and micro-CT analysis. It was concluded that collagen
modification of implant surfaces did not improve peri-
implant bone formation.
Stadlinger et al. [56] evaluated whether extracellular
matrix coating on implant surfaces increases bone for-
mation in minipigs. Six different implant surfaces were
created and tested in the maxillae of 20 minipigs: (1)
SAE Ti implant; (2) collagen type I coated implants; (3)
collagen type I + low amount of CS ; (4) collagen type I +
high amount of CS; (5) collagen type I + high-sulfate hya-
luronan; and (6) collagen type I + low-sulfate hyaluronan.
The BIC and BV density were measured using histomor-
phometric analysis at 4 and 8 weeks after implant place-
ment. ISQ values were obtained for implant stability.
Implants coated with the lower CS and collagen showed
significantly more BIC compared to all other groups at
4 weeks. However, the only significant difference in BIC
at 8 weeks was found between the lower CS group and
the control group. The differences in BV density and
ISQ value were not statistically significant at both 4
and 8 weeks. In addition, a higher concentration of CS
and the application of sulfate hyaluronan exhibited no
increase in BIC. It was concluded that the coating of
extracellular matrix exhibited no beneficial effect in the
aspect of BV density and ISQ value.
In the tibiae of rabbits, Lee et al. [57] studied whether
implant surfaces coated with HA and type I collagen
influence peri-implant bone formation. Four different
implant surfaces were prepared and tested in 12 New
Zealand rabbits: (1) uncoated control (acid-etched); (2)
HA coated; (3) collagen +HA coated; and (4) collagen +
HA + BMP-2. Peri-implant bone formation and BIC
were assessed by histomorphometric analysis 6 weeks
after implant placement. Under the histomorphometric
analysis, only the collagen + HA coating surfaces dis-
played significantly greater peri-implant bone formation
and BIC. Furthermore, adding BMP-2 to the implant
surface did not show any advantage compared to the
collagen + HA coating surface. It was concluded that
collagen and HA coatings significantly increased new
bone formation and BIC compared to the other coat-
ings, and the additional BMP-2 coating did not display
further benefits.
Discussion
The primary intention of endosseous implant surface
modifications is to absolutely modulate the implant and
host tissue response and accomplish better osseointegra-
tion. This review evaluated whether bioactive surface
modifications are capable of enhancing osseointegration
in comparison to uncoated titanium surfaces in animals.
This review has identified 34 research articles that used
histomorphometric analysis to evaluate peri-implant
bone formation in animals. Four categories of biomo-
lecular coatings, including BMP, non-BMP growth fac-
tors, peptides, and ECM, were established in this
review. Several different animal models were used in
these 34 studies, suggesting different dynamics of bone
formation especially in early healing times [58]. These
factors may influence for the observed BIC values.
Four out of 8 BMP coating studies reported a positive
effect on implant osseointegration [25, 26, 30, 31].
Among those 4 studies, two studies demonstrated a
positive effect only with higher concentrations of BMP.
Five out of 8 of the other growth factor coating studies
reported an encouraging effect on peri-implant bone for-
mation [32–34, 37, 39]. Whereas, 4 out of 5 studies in
the peptide coating category exhibited a promising effect
on osseointegration [40, 42–44]. Among those 4 studies,
two of them reported a positive effect only at the early
healing stage. Finally, there were 7 out of 13 studies for
the ECM coating group that revealed a positive effect on
bone formation. Two of the 7 studies showed that
osseointegration was enhanced when two types of ECM
were coated on implant surfaces. Therefore, bioactive
surface modifications on implant surfaces do not always
offer a beneficial effect on osseointegration. This review
is partially in line with the systematic review and meta-
analysis conducted by Jenny et al. [59]
One reason for the observed BIC variances in different
animals could be the overall faster bone regeneration in
dogs compared to pigs [59]. Therefore, the observed BIC
may not reflect the actual effect of the specific type of
surface modification on osseointegration in different
animal models. Another factor that may influence peri-
implant bone formation is the anatomic location of the
implant placement as the dynamics of bone formation
differ in different locations. It was reported that the
percentage of BIC for implants coated with growth fac-
tors increased in extraoral locations and decreased in
intraoral ones [59]. Furthermore, the time of healing in
different animals may also play a critical role in the as-
pect of osseointegration. Implant healing time showed
large variation ranging from 1 week to 6 months. How-
ever, some studies assessed a single time point, while
others evaluated up to four time points.
In summary, the present review assessed the impact of
bioactive surface modifications on implant osseointegration.
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It was difficult to conclude that biological implant sur-
face coating offers a beneficial effect on peri-implant
bone formation. Readers must keep in mind that all
these factors make the inter-study comparison more
difficult and further complicate the interpretation of
results. Furthermore, long-term prospective clinical
studies in humans are required to verify whether a posi-
tive effect in animals will translate to humans.
Conclusions
Bioactive surface modifications on implant surfaces do
not always offer a beneficial effect on osseointegration.
Nevertheless, surface modifications of titanium dental
implants with biomolecular coatings seem to promote
peri-implant bone formation, resulting in enhanced
osseointegration during the early stages of healing. Several
factors make the inter-study comparison more difficult
and further complicate the interpretation of results in
peri-implant bone formation. However, long-term clinical
studies are needed to validate the long-term success of
biomolecular coated implants. Furthermore, it must be
kept in mind that results of animal experiments need not
necessarily reflect the human clinical reality.
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